乳腺癌患者的心脏发病率和死亡率：综述。
Cardiac morbidity & mortality in patients with breast cancer: A review.
机构信息
Department of Medicine, Tata Memorial Hospital, Mumbai, Maharashtra, India.
出版信息
Indian J Med Res. 2021 Aug;154(2):199-209. doi: 10.4103/ijmr.IJMR_879_20.
Abstract
Cardiovascular disease (CVD) and breast cancer cause substantial morbidity and mortality in women and are major public health concerns. Breast cancer survivors are at a greater risk for CVD-related mortality compared to women without breast cancer. Breast cancer and cardiovascular diseases share a number of common risk factors. Breast cancer treatments like anthracycline based chemotherapy, novel targeted therapy and radiation therapy can cause cardiotoxicity. With improvements in breast cancer prevention and treatment, there is a significant improvement in survival and this shifts focus from disease control to long term effects of treatment and quality of life. Assessing CVD and minimizing complications from cancer therapy are important treatment goals.
摘要
心血管疾病（CVD）和乳腺癌在女性中导致大量发病率和死亡率，是主要的公共卫生关注点。与没有乳腺癌的女性相比，乳腺癌幸存者患与 CVD 相关的死亡率的风险更高。乳腺癌和心血管疾病有许多共同的危险因素。乳腺癌治疗，如基于蒽环类药物的化疗、新型靶向治疗和放射治疗，可导致心脏毒性。随着乳腺癌预防和治疗的改善，生存率显著提高，这将重点从疾病控制转移到治疗的长期影响和生活质量上。评估 CVD 并最大限度地减少癌症治疗的并发症是重要的治疗目标。
相似文献
1
Cardiac morbidity & mortality in patients with breast cancer: A review.乳腺癌患者的心脏发病率和死亡率：综述。
Indian J Med Res. 2021 Aug;154(2):199-209. doi: 10.4103/ijmr.IJMR_879_20.
2
New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.乳腺癌治疗药物对心脏和血管毒性的新认识。
Med Sci (Basel). 2022 May 25;10(2):27. doi: 10.3390/medsci10020027.
3
Cardiotoxicity screening of long-term, breast cancer survivors-The CAROLE (Cardiac-Related Oncologic Late Effects) Study.长期乳腺癌幸存者的心脏毒性筛查 - CAROLE（心脏相关肿瘤晚期效应）研究。
Cancer Med. 2021 Aug;10(15):5051-5061. doi: 10.1002/cam4.4037. Epub 2021 Jul 10.
4
Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology.乳腺癌幸存者与心血管疾病：心脏肿瘤学的新方法
Curr Treat Options Cardiovasc Med. 2015 Dec;17(12):60. doi: 10.1007/s11936-015-0421-y.
5
Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments.非化疗转移性乳腺癌治疗的心脏毒性
Curr Oncol Rep. 2023 Aug;25(8):923-935. doi: 10.1007/s11912-023-01427-z. Epub 2023 May 30.
6
Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer.转移性乳腺癌患者心脏功能障碍的预防、监测和管理。
Oncologist. 2019 Nov;24(11):e1034-e1043. doi: 10.1634/theoncologist.2018-0773. Epub 2019 May 7.
7
Management of Cardiovascular Disease in Women With Breast Cancer.乳腺癌女性心血管疾病的管理。
Circulation. 2019 Feb 19;139(8):1110-1120. doi: 10.1161/CIRCULATIONAHA.118.039371.
8
Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.早期乳腺癌的个体化决策：应用临床预测模型评估蒽环类药物心脏毒性和乳腺癌死亡率显示获益-风险权衡存在显著异质性。
Clin Breast Cancer. 2019 Aug;19(4):259-267.e1. doi: 10.1016/j.clbc.2019.04.012. Epub 2019 May 2.
9
Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: An observational study.葡萄牙一所三级大学医院心脏肿瘤会诊的临床经验：一项观察性研究。
Rev Port Cardiol. 2022 Dec;41(12):979-984. doi: 10.1016/j.repc.2021.07.014. Epub 2022 Sep 22.
10
Cardiotoxicity of Agents Used in Patients With Breast Cancer.用于乳腺癌患者的药物的心脏毒性。
JCO Oncol Pract. 2024 Jan;20(1):38-46. doi: 10.1200/OP.23.00494. Epub 2023 Nov 20.
引用本文的文献
1
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy.既往虚弱对接受辅助治疗的乳腺癌患者心脏毒性的影响。
JACC CardioOncol. 2025 Feb;7(2):110-121. doi: 10.1016/j.jaccao.2024.10.012. Epub 2025 Jan 7.
2
Effect of different intraoperative blood pressure regulation levels on postoperative myocardial injury in patients undergoing radical mastectomy for breast cancer after receiving neoadjuvant chemotherapy: a study protocol for a randomised controlled trial.新辅助化疗后行乳腺癌根治术患者不同术中血压调控水平对术后心肌损伤的影响：一项随机对照试验的研究方案
BMJ Open. 2025 Jan 6;15(1):e088559. doi: 10.1136/bmjopen-2024-088559.
3
The impacts of cancer treatment on lifestyle habits and mental health in Vietnamese women: an exploratory qualitative study.癌症治疗对越南女性生活习惯和心理健康的影响：一项探索性定性研究。
Support Care Cancer. 2024 Sep 11;32(10):654. doi: 10.1007/s00520-024-08831-6.
4
Rate of adverse cardiovascular events in breast cancer patients receiving chemotherapy and targeted therapy: Impact of frailty.接受化疗和靶向治疗的乳腺癌患者不良心血管事件发生率：虚弱的影响。
Am Heart J Plus. 2023 Dec 7;38:100353. doi: 10.1016/j.ahjo.2023.100353. eCollection 2024 Feb.
5
Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients.乳腺癌患者蒽环类药物所致心脏毒性的种族差异
Biomedicines. 2023 Aug 17;11(8):2286. doi: 10.3390/biomedicines11082286.
6
An integrative review of nonobvious puzzles of cellular and molecular cardiooncology.细胞与分子心脏肿瘤学不明显难题的综合回顾。
Cell Mol Biol Lett. 2023 May 23;28(1):44. doi: 10.1186/s11658-023-00451-y.
7
Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study.乳腺癌患者癌症治疗相关心血管毒性的长期及实际发生率：一项瑞典队列研究
Front Oncol. 2023 Apr 19;13:1095251. doi: 10.3389/fonc.2023.1095251. eCollection 2023.
8
Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway.丹皮酚通过激活 PKCε-Stat3 通路促进 Mfn2 介导的线粒体融合，从而防止阿霉素引起的心脏毒性。
J Adv Res. 2023 May;47:151-162. doi: 10.1016/j.jare.2022.07.002. Epub 2022 Jul 14.
本文引用的文献
1
Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy.应变引导的潜在心脏毒性癌症治疗管理。
J Am Coll Cardiol. 2021 Feb 2;77(4):392-401. doi: 10.1016/j.jacc.2020.11.020. Epub 2020 Nov 18.
2
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.预防癌症幸存者蒽环类药物所致心脏毒性的策略。
Cardiooncology. 2019 Dec 2;5:18. doi: 10.1186/s40959-019-0054-5. eCollection 2019.
3
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.癌症患者在肿瘤治疗全程中心血管疾病的管理：ESMO 共识推荐。
Ann Oncol. 2020 Feb;31(2):171-190. doi: 10.1016/j.annonc.2019.10.023.
4
Global longitudinal strain is a better metric than left ventricular ejection fraction: lessons learned from cancer therapeutic-related cardiac dysfunction.整体纵向应变优于左心室射血分数：癌症治疗相关心功能障碍的经验教训。
Curr Opin Cardiol. 2020 Mar;35(2):170-177. doi: 10.1097/HCO.0000000000000716.
5
The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond.《心血管疾病及其危险因素的全球负担：2020年及以后》
J Am Coll Cardiol. 2019 Nov 19;74(20):2529-2532. doi: 10.1016/j.jacc.2019.10.009.
6
Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol.质子与光子放疗治疗非转移性乳腺癌患者的实用随机临床试验：放射治疗比较效果（RadComp）联盟试验方案。
BMJ Open. 2019 Oct 15;9(10):e025556. doi: 10.1136/bmjopen-2018-025556.
7
Fluoropyrimidine-Associated Cardiotoxicity.氟嘧啶类药物相关性心脏毒性。
Cardiol Clin. 2019 Nov;37(4):399-405. doi: 10.1016/j.ccl.2019.07.004. Epub 2019 Aug 26.
8
Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.左心室整体纵向应变评估对化疗诱导性心脏毒性早期预测的预后价值：系统评价和荟萃分析。
JAMA Cardiol. 2019 Oct 1;4(10):1007-1018. doi: 10.1001/jamacardio.2019.2952.
9
Cancer treatment and survivorship statistics, 2019.2019 年癌症治疗与生存统计
CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11.
10
Breast Radiotherapy and Early Adverse Cardiac Effects. The Role of Serum Biomarkers and Strain Echocardiography.乳腺癌放疗与早期心脏不良效应。血清生物标志物和应变超声心动图的作用。
Anticancer Res. 2019 Apr;39(4):1667-1673. doi: 10.21873/anticanres.13272.
Zotero 插件